What was the main purpose of this 8-K filing?

The main purpose of this 8-K filing was to disclose that Becton, Dickinson and Company (BDX) will not proceed with the sale of its critical care product line to AorTech International plc, as AorTech has decided not to complete the acquisition.

What is the financial impact of AorTech backing out of the deal?

The primary financial impact is that BDX will not incur the loss on sale that was previously expected to be recognized in its fiscal 2002 third quarter earnings. The company will continue to operate this product line.

Does BDX still plan to sell its critical care product line in the future?

This filing does not provide information about BDX's future plans for the critical care product line. It only states that the current acquisition by AorTech will not proceed and BDX will continue to manage the business.

Where can I find more details about the critical care product line?

Additional details about the critical care product line might be found in BDX's previous SEC filings, such as their Form 10-Q for the quarter ended June 30, 2002, which mentioned the expected loss on sale. However, this 8-K focuses solely on the termination of the acquisition.

BDX 8-K SEC Disclosure — Aug 23, 2002

Summary

Becton, Dickinson and Company (BDX) has filed a Form 8-K to report a material development regarding a potential divestiture. AorTech International plc has announced its decision not to proceed with the acquisition of BDX's critical care product line. This means BDX will continue to operate and support this business segment. As a direct consequence, BDX will not record the previously anticipated loss on sale of this product line in its fiscal 2002 third quarter earnings. Investors should note that this event alters the company's previously communicated financial expectations for the current quarter, as the impact of the divestiture and associated loss will not materialize.

Key Highlights

1AorTech International plc will not proceed with the acquisition of BDX's critical care product line.
2BDX will retain and continue to manage its critical care product line.
3The anticipated loss on sale of the critical care product line will not be recognized by BDX.
4This decision impacts the previously reported expected financial results for the fiscal 2002 third quarter.
5The company will continue to support the critical care product line.

BECTON DICKINSON & CO 8-K Report (Aug 23, 2002)

Summary

Key Highlights

Frequently Asked Questions